MENGFEN MOSELEY: Open Payments
NPI 1720316979 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,682 in 73 payments from 7 companies in 2025. Trend: 2023 $1,249 · 2024 $1,775 · 2025 $1,682
Food & beverage: $1,673Education: $9
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 28 | $591 |
| Janssen Pharmaceuticals, Inc | 9 | $258 |
| Teva Pharmaceuticals USA, Inc. | 9 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $210 |
| E.R. Squibb & Sons, L.L.C. | 11 | $194 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Neurocrine BioSciences, Inc. | 3 | $84 |
Products named: ARISTADA, INVEGA SUSTENNA, UZEDY, CAPLYTA, COBENFY, ABILIFY ASIMTUFII, INGREZZA.
Industry payments across CA — which companies pay providers there.
